Revit Sp. z o.o. — Clinical Trial Site

15 Registered trials

4 Currently recruiting

Organisation

Revit Sp. z o.o.

Location

Bialystok, Poland

Identifier

ORG-100044322

Address

Ul. Swobodna 38, 15-756, Poland

Departments

#40603:Podlaskie Centrum Psychogeriatrii
Centrum Zdrowia Psychicznego Revit
N/A
NA
Not applicable
Podlaskie Centrum Psychogeriatrii
Private Practice

Clinical trials at this site (15)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
First-in-Human Study of RO7812653 Recruiting

2025-522101-37-00 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cogn 1 2026-02-17
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Alzheimer Disease Dementia Brain Diseases Central 5 2025-12-04
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early… Halted

2024-518523-30-00 early Alzheimer’s disease 4 2023-11-08
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended

2024-513435-24-01 Neuropathic Pain; Distal Sensory Polyneuropathy 4 2025-06-03
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain ( TRIUMPH-7 ) Ended

2024-517431-43-00 Overweight 5